Advanced search
Publication Cover
Nanotoxicology Volume 10, 2016 - Issue 8
Submit an article Journal homepage
293
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Poly(ortho ester) nanoparticles targeted for chronic intraocular diseases: ocular safety and localization after intravitreal injection

Huiling LiDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China, ;Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN, USA,
,
Mallika PalamoorDepartment of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN, USA,
&
Monica M. JablonskiDepartment of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN, USA, ;Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, Memphis, TN, USA, and ;Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, USACorrespondence[email protected]
Pages 1152-1159 | Received 03 Nov 2015, Accepted 15 Apr 2016, Published online: 16 May 2016

References

  • Ambati J, Adamis AP. 2002. Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res 21:145–51
  • Barnett NL, Osborne NN. 1995. Prolonged bilateral carotid artery occlusion induces electrophysiological and immunohistochemical changes to the rat retina without causing histological damage. Exp Eye Res 61:83–90
  • Bu HZ, Gukasyan HJ, Goulet L, Lou XJ, Xiang C, Koudriakova T. 2007. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab 8:91–107
  • Del Amo EM, Urtti A. 2008. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 13:135–43
  • Diebold Y, Calonge M. 2010. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 29:596–609
  • Einmahl S, Ponsart S, Bejjani RA, D'Hermies F, Savoldelli M, Heller J, et al. 2003. Ocular biocompatibility of a poly(ortho ester) characterized by autocatalyzed degradation. J Biomed Mater Res A 67:44–53
  • Erickson PA, Fisher SK, Guerin CJ, Anderson DH, Kaska DD. 1987. Glial fibrillary acidic protein increases in Muller cells after retinal detachment. Exp Eye Res 44:37–48
  • Geroski DH, Edelhauser HF. 2000. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci 41:961–4
  • Jablonski MM, Iannaccone A. 2001. Lactose supports Muller cell protein expression patterns in the absence of the retinal pigment epithelium. Mol Vis 7:27–35
  • Kaur IP, Kakkar S. 2014. Nanotherapy for posterior eye diseases. J Control Release 193:100–12
  • Kerr JF, Wyllie AH, Currie AR. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239–57
  • Kompella UB, Amrite AC, Pacha Ravi R, Durazo SA. 2013. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res 36:172–98
  • Kompella UB, Kadam RS, Lee VH. 2010. Recent advances in ophthalmic drug delivery. Ther Deliv 1:435–56
  • Myles ME, Neumann DM, Hill JM. 2005. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 57:2063–79
  • Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. 2009. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release 136:2–13
  • Nagarwal RC, Singh PN, Kant S, Maiti P, Pandit JK. 2010. Chitosan coated PLA nanoparticles for ophthalmic delivery: characterization, in-vitro and in-vivo study in rabbit eye. J Biomed Nanotechnol 6:648–57
  • Palamoor M, Jablonski M. 2013a. Comparative study on diffusion and evaporation emulsion methods used to load hydrophilic drugs in poly(ortho ester) nanoparticle emulsions. Powder Technol 53:53–62
  • Palamoor M, Jablonski M. 2013b. Poly(ortho ester) nanoparticle-based targeted intraocular therapy for controlled release of hydrophilic molecules. Mol Pharm 10:701–8
  • Palamoor M, Jablonski M. 2013c. Synthesis, characterization and in vitro studies of celecoxib-loaded poly(ortho ester) nanoparticles targeted for intraocular drug delivery. Colloids Surf B Biointerfaces 112:474–82
  • Reimondez-Troitino S, Csaba N, Alonso MJ, De La Fuente M. 2015. Nanotherapies for the treatment of ocular diseases. Eur J Pharm Biopharm 95:279–93
  • Sarthy V. 2007. Focus on molecules: glial fibrillary acidic protein (GFAP). Exp Eye Res 84:381–2
  • Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA, Post-Injection Endophthalmitis Study Team. 2011. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 118:2028–34
  • Shah SS, Denham LV, Elison JR, Bhattacharjee PS, Clement C, Huq T, Hill JM. 2010. Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Rev Ophthalmol 5:75–93
  • Shahar J, Zemel E, Perlman I, Loewenstein A. 2012. Physiological and toxicological effects of cefuroxime on the albino rabbit retina. Invest Ophthalmol Vis Sci 53:906–14
  • Short BG. 2008. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol 36:49–62
  • Swaminathan S, Li H, Palamoor M, De Obarrio WT, Madhura D, Meibohm B, Jablonski MM. 2014. Novel endogenous glycan therapy for retinal diseases: safety, in vitro stability, ocular pharmacokinetic modeling, and biodistribution. AAPS J 16:311–23
  • Woldemussie E, Wijono M, Ruiz G. 2004. Müller cell response to laser-induced increase in intraocular pressure in rats. Glia 47:109–19
  • Zhou HY, Hao JL, Wang S, Zheng Y, Zhang WS. 2013. Nanoparticles in the ocular drug delivery. Int J Ophthalmol 6:390–6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.